MMPP Anticancer Composition Inhibiting STAT3 DNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges due to increased NF-κB activity leading to multidrug resistance and poor response to anticancer drugs, as well as sustained activation of STAT3 promoting tumor growth and survival, which complicates effective cancer therapy.
Innovation Solution
A pharmaceutical composition containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol (MMPP) is developed, which inhibits the DNA binding activity of STAT3, induces apoptosis, and reduces expression of cell cycle regulatory proteins, thereby inhibiting cancer cell growth and tumor development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NF-κB activity is increased in cancer cells, then cell proliferation and survival are enhanced, but multidrug resistance increases and therapeutic effect decreases
Solution Approach 1:
The patent extracts and inhibits the specific harmful component NF-κB from the cancer cell signaling pathway. By using MMPP to selectively inhibit NF-κB activation, the patent removes the source of multidrug resistance and apoptosis suppression, thereby restoring sensitivity to anticancer drugs without affecting other cellular functions
Solution Approach 2:
The patent changes the activation state of NF-κB from sustained/activated to inhibited. MMPP alters the parameter of NF-κB activity by preventing its activation, which transforms the cancer cell state from resistant to sensitive, thereby improving therapeutic response
2Reliability
If STAT3 is continuously activated in cancer cells, then tumor growth and survival are promoted, but response to cancer therapy is reduced
Solution Approach 1:
The patent extracts and inhibits the continuously activated STAT3 from cancer cells. MMPP specifically targets and inhibits STAT3 activation, removing the driving force of tumor growth and survival, which enables cancer cells to respond appropriately to anticancer therapies
Solution Approach 2:
The patent applies preliminary inhibition of STAT3 activation before cancer therapy. By using MMPP to pre-inhibit STAT3, the patent prevents the activation of survival pathways that would otherwise protect cancer cells from therapy, thereby improving treatment efficacy
3Quantity of substance
If NF-κB activation pathway is disordered, then inflammatory mediators and immune substances continuously increase, but the condition becomes similar to autoimmune diseases
Solution Approach 1:
The patent introduces negative feedback inhibition of the NF-κB activation pathway. MMPP acts as a feedback inhibitor that detects and suppresses excessive NF-κB activation, thereby preventing the continuous increase of inflammatory mediators and avoiding autoimmune-like conditions while maintaining necessary immune function
Data Source
AI summary
The present disclosure relates to an anticancer use of a novel compound, i.e., 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol. The compound of the present disclosure effectively inhibits the growth of cancer cells and tumors in vitro and in a xenograft animal model. The compound of the present disclosure illustrates an anticancer activity by inhibiting a DNA binding activity of transcription factor STAT 3 in cancer cells, inducing apoptosis of cancer cells, and reducing the expression of a cell cycle regulatory protein. The compound of the present disclosure can be developed as an active ingredient of a strong anticancer drug.